Literature DB >> 24687566

Using Rasch analysis to examine the distress thermometer's cut-off scores among a mixed group of patients with cancer.

Sylvie D Lambert1, Julie F Pallant, Kerrie Clover, Benjamin Britton, Madeleine T King, Gregory Carter.   

Abstract

PURPOSE: The distress thermometer (DT) is commonly used in cancer care to improve detection of distress. The DT's recommended cut-off score of 4 or 5 has typically been established using the Hospital Anxiety and Depression Scale (HADS) by receiver operating characteristic curve analysis. The present analysis complements these studies by critically examining the use of the HADS to identify the DT's cut-off score and corroborating the DT's cut-off scores using item response theory (Rasch analysis).
METHODS: The DT and HADS were completed by 340 patients with cancer. Rasch dimensionality analysis was performed on the HADS-Total, and test characteristic curves were examined to equate the DT and the HADS subscales. Identified DT cut-off scores were then examined for their sensitivity and specificity.
RESULTS: Rasch analysis did not support the unidimensionality of HADS-Total. The test characteristic curves indicated that a cut-off score of ≥8 on the HADS-Anxiety and HADS-Depression subscales was equivalent to a score of 6 and 7 on the DT, respectively. However, a DT cut-off score of 5 resulted in the best balance between sensitivity and specificity across the HADS-Anxiety and HADS-Depression subscales.
CONCLUSIONS: Despite being a popular practice, the present findings did not support combining the HADS-Anxiety and HADS-Depression subscales to identify the DT's cut-off score. Furthermore, these results inform the use of the DT as a preliminary screening tool and suggest that when a single screen is used, a DT cut-off score of 6 or 7 might be more appropriate than the typical cut-off score of 4.

Entities:  

Mesh:

Year:  2014        PMID: 24687566     DOI: 10.1007/s11136-014-0673-0

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  44 in total

Review 1.  Understanding sensitivity and specificity with the right side of the brain.

Authors:  Tze-Wey Loong
Journal:  BMJ       Date:  2003-09-27

Review 2.  The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?

Authors:  Alan Tennant; Philip G Conaghan
Journal:  Arthritis Rheum       Date:  2007-12-15

3.  How does the Distress Thermometer compare to the Hospital Anxiety and Depression Scale for detecting possible cases of psychological morbidity among cancer survivors?

Authors:  Allison Boyes; Catherine D'Este; Mariko Carey; Christophe Lecathelinais; Afaf Girgis
Journal:  Support Care Cancer       Date:  2012-05-24       Impact factor: 3.603

4.  A confirmatory factor analysis of the Hospital Anxiety and Depression scale: comparing empirically and theoretically derived structures.

Authors:  M Dunbar; G Ford; K Hunt; G Der
Journal:  Br J Clin Psychol       Date:  2000-03

5.  The utility of the Edmonton Symptom Assessment System in screening for anxiety and depression.

Authors:  S M Bagha; A Macedo; L M Jacks; C Lo; C Zimmermann; G Rodin; M Li
Journal:  Eur J Cancer Care (Engl)       Date:  2012-06-14       Impact factor: 2.520

6.  Acceptability of common screening methods used to detect distress and related mood disorders-preferences of cancer specialists and non-specialists.

Authors:  Alex J Mitchell; Stephen Kaar; Chris Coggan; Joanne Herdman
Journal:  Psychooncology       Date:  2008-03       Impact factor: 3.894

7.  Screening for distress in cancer patients: a multicenter, nationwide study in Italy.

Authors:  Luigi Grassi; Christoffer Johansen; Maria Antonietta Annunziata; Eleonora Capovilla; Anna Costantini; Paolo Gritti; Riccardo Torta; Marco Bellani
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

8.  A Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) among cancer survivors.

Authors:  Sylvie D Lambert; Julie F Pallant; Allison W Boyes; Madeleine T King; Benjamin Britton; Afaf Girgis
Journal:  Psychol Assess       Date:  2013-01-28

9.  IPOS Sutherland Memorial Lecture: an international perspective on the development of psychosocial oncology: overcoming cultural and attitudinal barriers to improve psychosocial care.

Authors:  Jimmie C Holland
Journal:  Psychooncology       Date:  2004-07       Impact factor: 3.894

10.  High levels of untreated distress and fatigue in cancer patients.

Authors:  L E Carlson; M Angen; J Cullum; E Goodey; J Koopmans; L Lamont; J H MacRae; M Martin; G Pelletier; J Robinson; J S A Simpson; M Speca; L Tillotson; B D Bultz
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  4 in total

1.  A pilot, multisite, randomized controlled trial of a self-directed coping skills training intervention for couples facing prostate cancer: accrual, retention, and data collection issues.

Authors:  Sylvie D Lambert; Patrick McElduff; Afaf Girgis; Janelle V Levesque; Tim W Regan; Jane Turner; Hayley Candler; Cathrine Mihalopoulos; Sophy T F Shih; Karen Kayser; Peter Chong
Journal:  Support Care Cancer       Date:  2015-07-17       Impact factor: 3.603

2.  A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Authors:  Dina M Randazzo; Frances McSherry; James E Herndon; Mary Lou Affronti; Eric S Lipp; Charlene Flahiff; Elizabeth Miller; Sarah Woodring; Maria Freeman; Patrick Healy; Janet Minchew; Susan Boulton; Annick Desjardins; Gordana Vlahovic; Henry S Friedman; Stephen Keir; Katherine B Peters
Journal:  J Neurooncol       Date:  2017-07-01       Impact factor: 4.130

3.  Hope and Distress Are Not Associated With the Brain Tumor Stage.

Authors:  Simone Mayer; Stefanie Fuchs; Madeleine Fink; Norbert Schäffeler; Stephan Zipfel; Franziska Geiser; Heinz Reichmann; Björn Falkenburger; Marco Skardelly; Martin Teufel
Journal:  Front Psychol       Date:  2021-05-28

4.  Proactive community support tailored to holistic needs: A cohort study.

Authors:  Austyn Snowden; Jenny Young; Jan Savinc
Journal:  Cancer Med       Date:  2018-08-13       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.